Dr. Adam Kibel on Treating Bone Metastases in Prostate Cancer

Adam Kibel, MD

Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.

prostate cancer

Adam Kibel, MD, chief of urology, Dana Farber Cancer Institute, Brigham and Women's Hospital, discusses how to properly treatpatients with bone metastases and what the goals of the treatments are.

Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer. The combination significantly improved overall survival (OS), which Kibel says is proof enough to implement docetaxel in patients with bone metastatic cancer.